First Citizens Bank & Trust’s Corcept Therapeutics CORT Stock Holding History

First Citizens Bank & Trust’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$949K	Buy	10,916 +113	+1%	+$6.82K	0.01%	333
2026 Q1	$435K	Sell	10,803 -690	-6%	-$25.8K	0.01%	462
2025 Q4	$400K	Sell	11,493 -1,518	-12%	-$119K	0.01%	487
2025 Q3	$1.08M	Sell	13,011 -2,242	-15%	-$162K	0.02%	276
2025 Q2	$1.12M	Buy	15,253 +10,140	+198%	+$735K	0.02%	267
2025 Q1	$584K	Buy	+5,113	New	+$311K	0.01%	292
2021 Q3	–	Sell	-9,495	Closed	-$209K	–	418
2021 Q2	$209K	Buy	9,495 +685	+8%	+$15.2K	0.01%	398
2021 Q1	$210K	Buy	+8,810	New	+$235K	0.01%	376

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Citizens Bank & Trust's CORT Position: Q2 2026 in Review

First Citizens Bank & Trust increased its Corcept Therapeutics (CORT) stake by 1% in Q2 2026, buying an estimated $6.82K and bringing the position to 10,916 shares worth $949K. The position accounts for 0.01% of the portfolio, ranked #333.

First Citizens Bank & Trust first reported a position in CORT in Q1 2021 and has held it in 8 quarters since. The position peaked at $1.12M in Q2 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

First Citizens Bank & Trust held 10,916 shares of Corcept Therapeutics worth $949K as of Q2 2026.
First Citizens Bank & Trust bought 113 Corcept Therapeutics shares in Q2 2026, an estimated $6.82K.
Corcept Therapeutics made up 0.01% of First Citizens Bank & Trust's portfolio in Q2 2026, its #333 holding.
First Citizens Bank & Trust first reported a position in Corcept Therapeutics in Q1 2021 and has held it in 8 quarters since.
First Citizens Bank & Trust's Corcept Therapeutics position peaked at $1.12M in Q2 2025.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on First Citizens Bank & Trust's 13F filing for Q2 2026, filed 13 Jul 2026.